erlotinib hydrochloride has been researched along with omeprazole in 5 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (omeprazole) | Trials (omeprazole) | Recent Studies (post-2010) (omeprazole) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 9,085 | 2,737 | 1,487 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | omeprazole (IC50) |
|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | 3.1448 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.28 | |
| Potassium-transporting ATPase alpha chain 1 | Homo sapiens (human) | 1.45 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 2.315 | |
| Potassium-transporting ATPase subunit beta | Homo sapiens (human) | 1.45 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 1.7 | |
| Glutathione S-transferase omega-1 | Homo sapiens (human) | 4.6 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 1.7 | |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | 3.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D | 1 |
| Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M | 1 |
| Lin, C; Lin, G; Ma, J; Wang, S; Wang, X; Zhang, M; Zhang, Q; Zhou, Y | 1 |
| Abt, M; Ducray, PS; Giraudon, M; Hamilton, M; Kletzl, H; Lum, BL | 1 |
| Nagase, K; Ogawa, Y; Okano, M; Sai, Y; Shimada, T; Ueda, A; Yamada, M | 1 |
1 trial(s) available for erlotinib hydrochloride and omeprazole
| Article | Year |
|---|---|
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Ranitidine; Young Adult | 2015 |
4 other study(ies) available for erlotinib hydrochloride and omeprazole
| Article | Year |
|---|---|
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2013 |
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Omeprazole; Population Groups; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats.
Topics: Adjuvants, Anesthesia; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Erlotinib Hydrochloride; Hypoglycemic Agents; Limit of Detection; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenacetin; Protein Kinase Inhibitors; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tolbutamide | 2015 |
Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Erlotinib Hydrochloride; Food-Drug Interactions; Fruit and Vegetable Juices; Gastric Acid; Gastric Mucosa; Gastrointestinal Absorption; Hydrogen-Ion Concentration; Male; Malus; Omeprazole; Proton Pump Inhibitors; Rats, Wistar; Solubility | 2020 |